Neuropeptide Y Receptor NPY5R Identified as Promising Target for Lung Cancer Treatment | Research

The takeaway

High expression of the neuropeptide Y receptor NPY5R correlates with poor prognosis in lung adenocarcinoma, and a plant-derived compound targeting this receptor inhibited cancer cell growth and migration.

NPY5R = poor prognosis
High expression of this neuropeptide Y receptor in lung tumors correlates with worse patient outcomes and increased immune cell infiltration

What the researchers found

The study established NPY5R as a therapeutic target in lung adenocarcinoma through multiple lines of evidence:

- High NPY5R expression in lung tumors correlated with poor patient prognosis

- NPY5R expression was associated with immune cell infiltration in tumors

- Euphorbia Factor L2 (EFL2) targeted NPY5R and inhibited A549 lung cancer cell proliferation and migration while inducing cell death (apoptosis)

- Genetic knockdown of NPY5R further enhanced anti-tumor effects

- Combining NPY5R knockdown with EFL2 treatment synergistically activated ECM, PI3K-Akt, and MAPK pathways

- Four potential molecular targets downstream of NPY5R were identified via RNA sequencing

Why it matters

Lung adenocarcinoma is the leading cause of cancer deaths worldwide, and drug resistance limits current treatments. Identifying the neuropeptide Y receptor system as involved in cancer progression opens a completely new therapeutic avenue. NPY and its receptors are already well-studied in neuroscience and metabolism, meaning existing knowledge of this peptide system can be leveraged to accelerate cancer drug development targeting NPY5R.

How the study worked

The researchers used bioinformatics analyses to evaluate NPY receptor expression profiles and prognostic significance in lung adenocarcinoma. Experimental validation included lentivirus-mediated stable NPY5R knockdown in cancer cell lines, functional assays (CCK-8 proliferation, flow cytometry for apoptosis, scratch assays for migration), PRESTO-Tango receptor activation assays, RNA sequencing transcriptomic profiling, and qPCR validation.

What this study cannot tell us

This is entirely a preclinical study using cell lines and bioinformatics — no animal tumor models or human clinical data are included. The compound EFL2 is plant-derived and not yet characterized for drug-like properties (bioavailability, toxicity, pharmacokinetics). The cell line work was primarily in A549 cells, and results may differ in other lung cancer subtypes. The bioinformatics prognosis data are correlative and don't prove causation. No clinical drugs targeting NPY5R currently exist.

How to read the evidence

This is a preclinical study combining bioinformatics analysis with in vitro cell line experiments. While the multi-method approach provides converging evidence, the lack of in vivo animal models and clinical data means the findings are early-stage. The identification of NPY5R as a target is hypothesis-generating and requires significant further validation.

When this study was published

Published in 2026, this is a very recent study representing the emerging field of neuropeptide receptor targeting in oncology. No clinical drugs targeting NPY5R exist yet, making this truly frontier research.

The bigger picture

The neuropeptide Y system has been extensively studied for its roles in appetite regulation, stress response, and cardiovascular function. This study adds cancer biology to NPY's known functions, suggesting that tumor cells can co-opt neuropeptide signaling for growth and immune evasion. As more neuropeptide receptors are found to play roles in cancer, the peptide field may contribute an entirely new class of oncology targets beyond traditional chemotherapy and immunotherapy.

Questions still open

Can NPY5R-targeting drugs be developed with suitable drug-like properties for clinical use in lung adenocarcinoma?
Does NPY5R play a role in other cancer types beyond lung adenocarcinoma?
Could synthetic NPY peptide analogs that block NPY5R serve as anti-cancer agents, or is a small-molecule approach more viable?

Common questions

What is neuropeptide Y and what does it normally do?

Neuropeptide Y (NPY) is one of the most abundant peptides in the brain and nervous system. It regulates appetite, stress responses, blood pressure, and mood. NPY acts through several receptor subtypes (NPY1R through NPY5R). This study found that one of these receptors, NPY5R, is abnormally active in lung cancer, suggesting tumor cells are exploiting the neuropeptide signaling system to grow and evade the immune system.

Could this lead to new lung cancer treatments?

Potentially, but significant work remains. This study identifies NPY5R as a promising target and shows that a plant compound can inhibit cancer cells through this receptor. However, developing a drug requires years of optimization, animal testing, and clinical trials. No NPY5R-targeting drugs are currently in clinical use for any condition, so this represents a completely new direction for drug development.

Read the original research

Targeting NPY5R-A Member of the NPY Receptor Family: Pharmacological and Transcriptomic Mechanisms of the Euphorbia Factor L2 Against Lung Adenocarcinoma.

Pharmaceuticals (Basel, Switzerland), 19(2)

View on PubMed ↗Publisher’s paper ↗

Citation

Tao, Pengzhuo; Liu, Wei; Wang, Yongfu; Xue, Yajing; Liu, Changmin; Yuan, Yizhen; Leu, Kim Fey; Chen, Shilin; Song, Chi. (2026). Targeting NPY5R-A Member of the NPY Receptor Family: Pharmacological and Transcriptomic Mechanisms of the Euphorbia Factor L2 Against Lung Adenocarcinoma.. Pharmaceuticals (Basel, Switzerland), 19(2). https://doi.org/10.3390/ph19020322